Recent studies have shown that targeting Wnt/β-catenin signaling can boost the efficacy of anti-PD-1 immunotherapy in MM by exacerbating ferroptosis via regulation of MITF (Wang Y. et al., 2022). The gene discussed is PDCD1; the disease is Miyoshi myopathy.